Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
McKesson
Johnson and Johnson
Dow
Medtronic

Last Updated: January 20, 2020

DrugPatentWatch Database Preview

Patent: 9,028,800

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 9,028,800
Title:Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
Abstract: The present application discloses compositions and methods of synthesis and use of .sup.18F or .sup.19F-labeled molecules of use in PET, SPECT and/or MR imaging. Preferably, the .sup.18F or .sup.19F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex to a bifunctional chelating agent, which may be directly or indirectly attached to the targeting molecule. In other embodiments, the .sup.18F or .sup.19F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. The disclosed methods and compositions allow the simple and reproducible labeling of molecules at very high efficiency and specific activity in 30 minutes or less. In preferred embodiments, the labeled molecule may be used for imaging in a subject without purification after labeling.
Inventor(s): D\'Souza; Christopher A. (Pomona, NY), McBride; William J. (Boonton, NJ), Goldenberg; David M. (Mendham, NJ)
Assignee: Immunomedics, Inc. (Morris Plains, NJ)
Application Number:14/273,163
Patent Claims:see list of patent claims

Details for Patent 9,028,800

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial Immunomedics, Inc. (Morris Plains, NJ) 2027-01-11 RX search
Astrazeneca Ab FASENRA benralizumab INJECTABLE;INJECTION 761070 001 2017-11-14   Start Trial Immunomedics, Inc. (Morris Plains, NJ) 2027-01-11 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Immunomedics, Inc. (Morris Plains, NJ) 2027-01-11 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Immunomedics, Inc. (Morris Plains, NJ) 2027-01-11 RX Orphan search
Glaxosmithkline Llc BENLYSTA belimumab INJECTABLE;INJECTION 761043 001 2017-07-20   Start Trial Immunomedics, Inc. (Morris Plains, NJ) 2027-01-11 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Boehringer Ingelheim
McKinsey
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.